Latest Pfizer Canada Inc. Stories
TORONTO, May 1, 2013 /CNW/ - Pfizer Canada Inc., the Canadian distributor of EpiPen® (epinephrine auto-injector) is proud to partner with Indy Race Car driver Alex Tagliani in an exciting new initiative to promote food allergy awareness and safety. The Summer of TAG (Treating Allergies with Genuine Care), will support Alex's charity of choice, Anaphylaxis Canada, in their efforts to engage Canadians in a conversation about effective management of food allergies and what to do in...
MONTREAL, Feb. 15, 2013 /PRNewswire/ - The Government of Québec announced today a $10 million investment in the Personalized Medicine Partnership for Cancer (PMPC). This public-private partnership will be focused on establishing an integrated approach for the development and implementation of clinical biomarkers and other personalized healthcare solutions to improve the outcome and cost-efficiency of healthcare services provided to cancer patients in the province of Québec and...
Decision Allows for Broader Access to Vaccine for the Prevention of Pneumococcal Disease in Adults KIRKLAND, QC, Nov. 20, 2012 /CNW/ - Pfizer Canada announced today that the World Health Organization (WHO) has granted an expansion to the prequalification of Pfizer's pneumococcal conjugate vaccine, Prevnar 13, to include immunization of adults 50 years of age and older against pneumonia and invasive disease caused by the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14,...
Fifth Annual Awards Competition Dedicated to Independent Pain Research KIRKLAND, QC, June 12, 2012 /CNW/ - Pfizer Canada is pleased to announce the recipients of the 2011 Neuropathic Pain Research Awards, an annual grant competition for independent research in the areas of basic biomedical, clinical and health service and systems sciences.(1) "For the past five years, the Neuropathic Pain Research Awards have supported Canadian medical innovation and research in neuropathic...
XALKORI NOW AVAILABLE IN CANADA KIRKLAND, QC, May 30, 2012 /CNW/ - Pfizer Canada is pleased to announce that XALKORI(®) (crizotinib) is now available in Canada. Recently approved with conditions by Health Canada, XALKORI is an oral monotherapy for patients with anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC).(1) XALKORI is Pfizer Canada's first example of personalized medicine for people with ALK-positive non-small cell lung...
Xalkori Now Available in Canada KIRKLAND, QC, May 30, 2012 /CNW/ - Pfizer Canada is pleased to announce that XALKORI(®) (crizotinib) is now available in Canada. Recently approved with conditions by Health Canada, XALKORI is an oral monotherapy for patients with anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC).(1) XALKORI is Pfizer Canada's first example of personalized medicine for people with ALK-positive non-small cell lung...
Pfizer Canada Inc. and WestJet offer suggestions for a safer and less stressful travel experience KIRKLAND, QC and CALGARY, AB, May 15, 2012 /CNW/ - Pfizer Canada Inc., makers of EpiPen(®) (epinephrine) Auto-Injector, and WestJet today announced results of a survey commissioned to determine the concerns of Canadians at risk of anaphylaxis who may be travelling this summer. A total of 666 Canadian adults, who were all prescreened as being at risk of anaphylaxis,(a) or as...
